| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Sep'14 | Sep'13 |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net Income (Loss) Attributable to Parent | ||||||
14,313 | 31,903 | 51,943 | 81,453 | 2,571 | -17,977 | -6,048 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
Deferred income taxes | ||||||
152 | -2,468 | 17,289 | -30,116 | 0 | 0 | - |
Depreciation expense | ||||||
2,131 | 1,155 | 932 | 641 | 112 | 104 | - |
Amortization expense | ||||||
2,520 | 2,515 | 2,815 | 948 | 0 | 0 | - |
Depreciation and amortization expense | ||||||
- | - | - | - | - | - | 135 |
Stock-based compensation expense | ||||||
21,998 | 19,082 | 15,429 | 9,768 | 4,051 | 606 | 317 |
Change in fair value of contingent consideration | ||||||
0 | -763 | -7,377 | 957 | 0 | 0 | - |
Non-cash interest expense | ||||||
- | - | - | - | - | - | 309 |
Amortization of debt issuance costs | ||||||
480 | 376 | 222 | 0 | 0 | - | 96 |
Gain (Loss) on Disposition of Assets | ||||||
- | - | - | 1,750 | 0 | 0 | - |
Asset impairment charge | ||||||
0 | 2,704 | 7,235 | 0 | 0 | - | - |
Non-cash restructuring charge | ||||||
0 | 5,769 | 0 | 0 | - | - | - |
Amortization of debt discount | ||||||
- | - | - | - | - | - | 1,091 |
Change in fair value of warrant liability | ||||||
- | - | - | - | - | 573 | 1,052 |
Loss on disposal of fixed assets | ||||||
- | - | - | - | -273 | 0 | 0 |
Changes in operating assets and liabilities which provided (used) cash: | ||||||
Accounts receivable | ||||||
-18,481 | 12,665 | 11,627 | 15,919 | 14,311 | 2,172 | 3,543 |
Inventories | ||||||
-1,739 | 5,556 | 2,379 | -12,303 | 13,800 | 1,294 | -87 |
Prepaid expenses and other current assets | ||||||
4,841 | -4,838 | -1,993 | 9,430 | 323 | -192 | 1,368 |
Other assets | ||||||
599 | 570 | 0 | 0 | - | -1 | -30 |
Accounts payable | ||||||
-4,455 | -2,064 | -8,460 | 10,668 | 356 | 2,867 | -251 |
Deferred revenue | ||||||
- | - | - | -6,000 | -520 | -3,435 | 520 |
Accrued expenses and other liabilities | ||||||
4,067 | 8,128 | -9,096 | -316 | 11,873 | 6,692 | 1,694 |
Net cash provided by operating activities | ||||||
55,986 | 52,384 | 58,919 | 53,207 | -9,718 | -13,843 | -5,879 |
Cash flows from investing activities: | ||||||
Purchase of property and equipment | ||||||
777 | 133 | 4,436 | 1,590 | 1,881 | 46 | 41 |
Purchase of short term investments | ||||||
- | - | - | 62,000 | 105,999 | 19,999 | 0 |
Maturities of short term investments | ||||||
- | - | - | 62,000 | 105,999 | 0 | 1,500 |
Payments to Acquire Businesses, Gross | ||||||
- | - | - | 4,850 | 0 | 0 | - |
Payment for Ryanodex intangible asset | ||||||
0 | 0 | 750 | 14,250 | 0 | 0 | - |
Purchase of Eagle Biologics, net of cash acquired | ||||||
- | - | - | 26,860 | 0 | 0 | - |
Proceeds from sale of diclofenac-misoprostol | ||||||
- | - | - | 1,750 | 0 | 0 | - |
Net cash used in investing activities | ||||||
-777 | -133 | -5,186 | -45,800 | -1,881 | -20,045 | 1,459 |
Cash flows from financing activities: | ||||||
Payments for employee net option exercises | ||||||
0 | 4,877 | 0 | - | - | - | - |
Proceeds from issuance of Series C preferred stock, net of offering costs of $160 | ||||||
- | - | - | - | - | - | 9,829 |
Deferred IPO costs | ||||||
- | - | - | - | - | - | -20 |
Series C preferred stock offering costs | ||||||
- | - | - | - | - | 1 | 0 |
Proceeds from exercise of preferred stock warrants | ||||||
- | - | - | - | - | 21 | 0 |
Proceeds from issuance of common stock from initial public offering, net of issuance costs | ||||||
- | - | - | - | - | 46,069 | 0 |
Proceeds from issuance of common stock from follow-on public offering, net of issuance costs | ||||||
- | - | - | - | 54,331 | 0 | 0 |
Proceeds from common stock option exercises | ||||||
260 | 8,615 | 4,338 | 3,619 | 1,482 | 65 | 0 |
Payment of debt financing costs | ||||||
326 | 0 | 1,192 | 0 | 0 | - | - |
Employee withholding taxes related to stock-based awards | ||||||
198 | 0 | 0 | 0 | - | - | - |
Payment of contingent consideration | ||||||
0 | 15,000 | 0 | 286 | 0 | 0 | - |
Proceeds from long-term debt | ||||||
0 | 0 | 50,000 | 0 | 0 | - | - |
Payment of debt | ||||||
6,000 | 3,750 | 1,250 | 0 | 0 | - | - |
Repurchases of common stock | ||||||
17,961 | 73,105 | 43,792 | 37,003 | 0 | 0 | - |
Net cash provided by (used in) financing activities | ||||||
-24,225 | -88,117 | 8,104 | -33,670 | 55,813 | 46,154 | 9,809 |
Net increase in cash and cash equivalents | ||||||
30,984 | -35,866 | 61,837 | -26,263 | 44,214 | 12,266 | 5,389 |
Supplemental disclosures of cash flow information: | ||||||
Cash paid during the period for: | ||||||
Interest | ||||||
2,478 | 2,084 | 651 | 8 | 11 | 8 | 0 |
Right-of-use asset obtained in exchange for lease obligation - lease amendment | ||||||
3,716 | 0 | 0 | - | - | - | - |
Supplemental disclosures of cash flow information: | ||||||
Cash paid during the period for: | ||||||
Financing costs | ||||||
- | - | - | - | - | - | 20 |
Income taxes, net | ||||||
6,673 | 2,281 | 10,542 | 2,800 | 482 | 0 | 0 |
Non-cash operating activities | ||||||
Landlord contribution to leasehold improvements recorded as deferred rent | ||||||
- | - | - | - | 367 | 0 | 0 |
Value of common stock issued for the Eagle Biologics acquisition | ||||||
- | - | - | 3,046 | 0 | - | - |
Contingent consideration - business acquisitions | ||||||
- | - | - | 22,470 | 0 | 0 | - |
Conversion of note payable to Preferred Stock | ||||||
- | - | - | - | - | - | 10,062 |
Franchise taxes | ||||||
- | - | - | - | - | - | 20 |
Accrued IPO costs | ||||||
- | - | - | - | - | - | 152 |